Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (Q91958139)
Jump to navigation
Jump to search
scientific article published on 09 May 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial |
scientific article published on 09 May 2019 |
Statements
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (English)
Toni K Choueiri
Brian I Rini
Thomas Powles
Michael B Atkins
Bernard Escudier
David F McDermott
Cristina Suarez
Sergio Bracarda
Walter M Stadler
Jae Lyun Lee
Robert Hawkins
Alain Ravaud
Boris Alekseev
Michael Staehler
Motohide Uemura
Begoña Mellado
Camillo Porta
Bohuslav Melichar
Jens Bedke
Francis Parnis
Tarik Khaznadar
Alpa Thobhani
Shi Li
Elisabeth Piault-Louis
Gretchen Frantz
Mahrukh Huseni
Christina Schiff
Marjorie C Green
Robert J Motzer
IMmotion151 Study Group